A narrative review of digital biomarkers in the management of major depressive disorder and treatment-resistant forms.

Journal: Frontiers in psychiatry
Published Date: Nov 23, 2023

Abstract

INTRODUCTION: Depression is the leading cause of worldwide disability, until now only 3% of patients with major depressive disorder (MDD) experiences full recovery or remission. Different studies have tried to better understand MDD pathophysiology and its resistant forms (TRD), focusing on the identification of candidate biomarkers that would be able to reflect the patients' state and the effects of therapy. Development of digital technologies can generate useful digital biomarkers in a real-world setting. This review aims to focus on the use of digital technologies measuring symptom severity and predicting treatment outcomes for individuals with mood disorders.

Authors

  • Annarita Vignapiano
    Department of Mental Health, Salerno, Italy.
  • Francesco Monaco
    Department of Mental Health, Salerno, Italy.
  • Claudio Pagano
    Dipartimento di Scienze Aziendali-Managment e Innovation Systems, Università di Salerno, Salerno, Italy.
  • Martina Piacente
    European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
  • Federica Farina
    European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
  • Gianvito Petrillo
    Innovation Tecnology e Sviluppo (I.T. Svil), Salerno, Italy.
  • Raffaella Sica
    Department of Mental Health, Salerno, Italy.
  • Alessandra Marenna
    European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
  • Jae Il Shin
    Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Marco Solmi
    Department of Psychiatry, University of Ottawa, Ontario, ON, Canada.
  • Giulio Corrivetti
    Department of Mental Health, Salerno, Italy.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals